The UK s speedy Covid vaccine rollout: Surprise success or planned perfection? devonlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from devonlive.com Daily Mail and Mail on Sunday newspapers.
With the UK on track to vaccinate all its priority groups with a first dose by mid-April, the target date for getting an initial vaccine to the rest of the British population has been brought forward by a month, to the end of July.
In conjunction with this, prime minister Boris Johnson has revealed his plan to bring the country out of lockdown. Although slow and cautious, the roadmap is broadly sensible, a panel of experts told The Conversation. It is split into four stages, and moving from each onto the next will rely on vaccine rollout continuing to go to plan. On this front, the current signs are positive.
Tensions Run High in Europe Over the Oxford-AstraZeneca Vaccine
The EU and AstraZeneca have publicly fallen out over delays to the EU’s order of COVID vaccines, which the manufacturer expects to be 60% lower than expected this spring.
It’s been a rollercoaster week for the Oxford-AstraZeneca vaccine, which has been authorised for use in the EU while simultaneously being at the heart two high-profile European disputes.
The EU and AstraZeneca have publicly fallen out over delays to the EU’s order of COVID vaccines, which the manufacturer expects to be 60% lower than expected this spring. As Aditya Goenka, Professor of Economics at the University of Birmingham, explains, this has been compounded by other supply woes, leaving the bloc short on doses and unable to speed up its already slow rollout.
How the EU barrelled into a crisis over Covid vaccine supply
At the moment, demand for COVID-19 vaccines is much higher than supply
Sarah Schiffling, Liverpool John Moores University
Daniel Smith
The video will auto-play soon8Cancel
Play now
Never miss a big story in Plymouth again with our daily newslettersInvalid EmailSomething went wrong, please try again later.
Sign me up!
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.
It’s been a rollercoaster week for the Oxford-AstraZeneca vaccine, which has been authorised for use in the EU while simultaneously being at the heart two high-profile European disputes.
The EU and AstraZeneca have publicly fallen out over delays to the EU’s order of COVID vaccines, which the manufacturer expects to be 60% lower than expected this spring. As Aditya Goenka, Professor of Economics at the University of Birmingham, explains, this has been compounded by other supply woes, leaving the bloc short on doses and unable to speed up its already slow rollout.
Specifically, it’s problems at a vaccine-production site in Belgium that have left Europe with this shortfall, say supply-chain experts Liz Breen and Sarah Schiffling, who then go on to explore the various issues that can hamper COVID vaccine production and what can be done to get around them.